Stocks to Watch, June 20: United Spirits, banking and NBFCs, Kaynes Tech, TD Power Systems, Oswal Pumps, ITD Cementation

Subsequently, NAO Spirits will become a subsidiary of the company, Diageo India said in a statement.

NAO Spirits is an emerging Indian craft spirits company, with brands such as 'Greater Than' and 'Hapusa'. It was launched in 2017 by Anand Virmani.

"The acquisition of NAO Spirits, a promising portfolio company within our Ventures arm, represents a pivotal step in exploring future growth opportunities in Indian craft spirits," Diageo India MD and CEO Praveen Someshwar said.

Deliveries under this order are scheduled to be completed between January 2026 and December 2027, the company said in a regulatory filing.

This order further demonstrates TDPS' technical expertise and trusted capabilities in delivering high-precision components that meet global standards, it said.

This order awarded by an international entity does not fall within the purview of related-party transactions, the company said.

Privi Speciality Chemicals' promoters – Bhaktavatsala Rao Doppalapudi, Vijaykumar Doppalapudi, Vinaykumar Doppalapudi Rao and Vivira Investment and Trading – sold a total of 16 lakh shares, or a 4.09% stake in the company, as per the bulk deal data on the NSE.

The transaction, valued at around ₹329.88 crore, was executed in the price range of ₹2,055-₹2,087.70 per share.

After the transactions, the combined promoter holding in Privi Speciality Chemicals declined to 69.96% from 74.05%.

“This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 26th June 2025, to inter alia consider and approve the proposal for issue of bonus shares, subject to the requisite approval,” Nestle India said in a regulatory filing dated June 19.

If passed by the board, this will be Nestlé India’s first bonus share issue.

The US Food and Drug Administration (USFDA) had conducted an inspection at the company's pharma division located in Kothur, Hyderabad, from June 9-19, 2025, Natco Pharma said in a regulatory filing.

"On conclusion of the inspection, the company received seven observations in the Form-483," it said.